Menu
PRISM will be accepting submissions for our next screen
January 27 – February 14, 2025!
This screen will be for DMSO-soluble small molecules only against the PRISM collection of 930 cancer cell lines.
PRISM will be accepting submissions for our next screen
January 27 – February 14, 2025!
This screen will be for DMSO-soluble small molecules only against the PRISM collection of 930 cancer cell lines.
Discovering the anticancer potential of non-oncology drugs by systematic viability profiling
Genetic dependencies associated with transcription factor activities in human cancer cell lines
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Tumor-selective activity of RAS-GTP inhibition in pancreatic cancer
Discovery and Characterization of Selective, First-in-Class Inhibitors of Citron Kinase
A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma
Targeting ROS production through inhibition of NADPH oxidases
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
Screening in serum-derived medium reveals differential response to compounds targeting metabolism
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors
Acute pharmacological degradation of ERK5 does not inhibit cellular immune response or proliferation
Massively parallel pooled screening reveals genomic determinants of nanoparticle delivery
Methionine synthase is essential for cancer cell proliferation in physiological folate environments
A metastasis map of human cancer cell lines
Pan-cancer single-cell RNA-seq identifies recurring programs of cellular heterogeneity
Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism
Mitochondrial metabolism promotes adaptation to proteotoxic stress
The landscape of cancer cell line metabolism
